A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting

Phase 2

Phase 3

RemternetugA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Sponsor:

Washington University School of Medicine

Code:

NCT06647498

Conditions

Alzheimers Disease

Dementia

Alzheimers Disease, Familial

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Remternetug

Matching Placebo (Remternetug)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-23. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2025-11-12.